Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $589.1 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 24.74% year-over-year to $589.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 billion (down 19.22% YoY) and the FY2025 annual result came in at $589.1 million, down 24.74% from the prior year.
• Liabilities and Shareholders Equity slipped to $589.1 million in Q4 2025, from $661.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $901.4 million in Q1 2024 to a low of $263.8 million in Q3 2022.
• A 5-year average of $529.5 million and a median of $455.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 108.51% — and 2025, when it slipped 24.74%.
• Tracing AUTL's Liabilities and Shareholders Equity over 5 years: stood at $405.6 million in 2021, then gained by 20.89% to $490.3 million in 2022, then fell by 23.43% to $375.4 million in 2023, then soared by 108.51% to $782.7 million in 2024, then fell by 24.74% to $589.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $589.1 million (Q4 2025), $661.9 million (Q3 2025), and $721.0 million (Q2 2025), per Business Quant data.